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Abstract
Purpose All clinical 89Zr-immuno-PET studies are cur-
rently performed with the chelator desferrioxamine
(DFO). This chelator provides hexadentate coordination
to zirconium, leaving two coordination sites available for
coordination with, e.g., water molecules, which are rela-
tively labile ligands. The unsaturated coordination of
DFO to zirconium has been suggested to result in im-
paired stability of the complex in vivo and consequently
in unwanted bone uptake of 89Zr. Aiming at clinical im-
provements, we report here on a bifunctional isothiocya-
nate variant of the octadentate chelator DFO* and the
in vitro and in vivo comparison of its 89Zr-DFO*-mAb
complex with 89Zr-DFO-mAb.
Methods The bifunctional chelator DFO*-pPhe-NCS was
prepared from previously reported DFO* and p-
phenylenediisothiocyanate. Subsequently, trastuzumab was
conjugated with either DFO*-pPhe-NCS or commercial
DFO-pPhe-NCS and radiolabeled with Zr-89 according to
published procedures. In vitro stability experiments were car-
ried out in saline, a histidine/sucrose buffer, and blood serum.
The in vivo performance of the chelators was compared in
N87 tumor-bearing mice by biodistribution studies and PET
imaging.
Results In 0.9 % NaCl 89Zr-DFO*-trastuzumab was more
stable than 89Zr-DFO-trastuzumab; after 72 h incubation at
2-8 °C 95 % and 58 % intact tracer were left, respectively,
while in a histidine-sucrose buffer no difference was ob-
served, both products were ≥ 92 % intact. In vivo uptake
at 144 h post injection (p.i.) in tumors, blood, and most
normal organs was similar for both conjugates, except for
skin, liver, spleen, ileum, and bone. Tumor uptake was
32.59 ± 11.95 and 29.06 ± 8.66 % ID/g for 89Zr-DFO*-
trastuzumab and 89Zr-DFO-trastuzumab, respectively. The
bone uptake was significantly lower for 89Zr-DFO*-
trastuzumab compared to 89Zr-DFO-trastuzumab. At
144 h p.i. for 89Zr-DFO*-trastuzumab and 89Zr-DFO-
trastuzumab, the uptake in sternum was 0.92 ± 0.16 and
3.33 ± 0.32 % ID/g, in femur 0.78 ± 0.11 and 3.85, ± 0.80
and in knee 1.38 ± 0.23 and 8.20 ± 2.94 % ID/g, respective-
ly. The uptake in bone decreased from 24 h to 144 h p.i.
about two fold for the DFO* conjugate, while it increased
about two fold for the DFO conjugate.
Conclusions Zr-DFO*-trastuzumab showed superior
in vitro stability and in vivo performance when compared
to 89Zr-DFO-trastuzumab. This makes the new octadentate
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Introduction
PET imaging with 89Zr-labeled monoclonal antibodies
(mAbs) or other targeted vehicles (e.g., peptides, nanoparti-
cles, and cells), collectively called 89Zr-immuno-PET, can be
used for better understanding of disease targets and the in vivo
behavior of targeted drugs [1]. 89Zr is ideally suited for this
purpose because its physical half-life of 78.4 h matches the
residence time of intact mAbs in the body (typically several
days). Moreover, 89Zr is a residualising radionuclide; when a
mAb internalises, 89Zr-mAbs give higher tumor-to-normal tis-
sue ratios than, e.g., the corresponding 124I-labeled mAbs [2]
resulting in better contrast on PET images.
The field of 89Zr-immuno-PET is expanding very rapidly
as exemplified by the increasing number of publications in
recent years, the types of applications, and the number of
clinical trials [1, 3]. Several factors are contributing to this
rapid expansion. First, mAbs are entering the mainstream of
targeted drug development and therapy [4]. The recent intro-
duction of the next generation of mAbs, characterised by in-
creased potency (e.g., antibody-drug conjugates and immune
checkpoint inhibiting mAbs), multiple binding domains, and/
or high costs, makes finding answers about their in vivo be-
havior in individual subjects even more urgent [5]. Second,
89Zr-immuno-PETappears to be ideally suited for quantitative
imaging of mAbs, and became technically matured by the
commercial supply of 89Zr and chelators, standard protocols
for 89Zr coupling to mAbs, and standardisation and
harmonisation of 89Zr-quantification by PET imaging [6–8].
The only chelator used thus far in the clinic for the com-
plexation of 89Zr is desferrioxamine (DFO). The fact that DFO
was clinically used for many years to counteract iron and
aluminum overload, has clearly facilitated the introduction
of DFO in clinical 89Zr-immuno-PET.Moreover, the first clin-
ical 89Zr-immuno-PET trial indicated that the chelator is not
immunogenic [9], and can, therefore, be used repeatedly. The
most often used conjugation procedures employ a 2,3,5,6-
tetrafluorophenol (TFP) activated ester of N-succinyl-DFO-
Fe (TFP-N-suc-DFO-Fe, in which DFO is protected by Fe3+)
or p-isothiocyanatobenzyl-DFO (p-SCN-Bn-DFO = DFO-
pPhe-NCS, Macrocyclics), forming stable amide or thiourea
bonds, respectively, with lysine residues of the proteins [6,
10–12]. Both bifunctional chelating agents are commercially
available and have been applied in clinical trials.
From an inorganic chemistry perspective, however, DFO is
not the optimal chelator for stable complexation of zirconium,
because DFO consists of three hydroxamate moieties and is a
hexadentate chelator, while 89Zr4+ prefers the formation of
octadentate complexes [13]. Although the resulting slightly
impaired stability of 89Zr-DFO-mAb does not really hamper
image quality, it is clear from preclinical studies that in time,
some 89Zr4+ becomes released from the conjugate and accu-
mulates in the bones [13–16]. For example, Perk et al. com-
pared the biodistribution of the conjugates 89Zr-DFO-
cetuximab, 88Y-DOTA-cetuximab and 177Lu-DOTA-
cetuximab in tumor-bearing nude mice [14]. While the overall
biodistribution of these conjugates was very similar, a signif-
icant higher uptake for 89Zr compared to 88Y and 177Lu was
observed in femur and sternum at 48–144 h p.i. Over time,
femur levels increased from about 2 %ID/g at 24 h p.i. to 6.9
%ID/g at 144 h p.i., indicating partial instability of the 89Zr-
DFO complex. Bone uptake of released 89Zr is unwanted,
since it will increase the radiation dose to the bone marrow,
impair detection of bone metastases, and disturb 89Zr-mAb
quantification in bone, bone marrow, and bone metastases.
An optimal chelating agent should be safe for clinical use,
efficiently conjugated to, e.g., mAbs and labeled with 89Zr,
not alter the biodistribution of the mAb, and, most important-
ly, be more stable in vitro and in vivo than DFO to prevent
gradual accumulation of 89Zr in the bones. In the past years,
several new chelators have been reported aiming at increased
89Zr-complex stability in vivo. Some chelators contain
hydroxamate moieties, like the linear and macrocyclic
tetrahydroxamate chelators reported by Guerard et al., and
the trihydroxamate chelators reported by Boros et al. and
Zhai et al. [17–20]. Other examples do not contain
hydroxamate moieties like p-SCN-Bn-H6phospha, 3,4,3-(LI-
1,2-HOPO), and 3-hydroxypyridin-2-one (2,3-HOPO) [16,
21–23]. However, none of these developments have led to a
bifunctional chelator that outperforms 89Zr-DFO-mAb com-
plexes on all abovementioned aspects of an optimal chelating
agent.
Recently, we reported the synthesis of a tetrahydroxamate
chelator called DFO* (DFO-star), and the high stability of its
89Zr-DFO*-complex as shown in challenging experiments
with DFO [24]. In the current paper, we describe the synthesis
of the bifunctional DFO*-pPhe-NCS, its coupling to mAbs,
and the subsequent labeling with 89Zr. Finally, 89Zr-DFO*-
mAb conjugates are compared with 89Zr-DFO-mAb conju-
gates for stability in vitro, and for biodistribution and PET
imaging in vivo in tumor-bearing mice with emphasis on
89Zr bone uptake.
Materials and methods
Details regarding the synthesis and analysis of DFO*-pPhe-
NCS, radiolabeling results of cetuximab and rituximab, and
examples of SEC-HPLC diagrams of 89Zr-DFO*-
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trastuzumab, 89Zr-DFO*-rituximab, and 89Zr-DFO*-
cetuximab can be found in the supplemental data.
Materials, monoclonal antibodies, cell lines, radioactivity,
and nomenclature
All reagents and solvents were purchased from Sigma
Aldrich. Trastuzumab (21 mg/mL) directed against human
epidermal growth factor receptor 2 (HER2), cetuximab
(5 mg/mL) directed against the epidermal growth factor recep-
tor (EGFR), and rituximab (10 mg/mL) directed against
CD20, were obtained from the VU University Medical
Center pharmacy. In the present study, DFO*-pPhe-NCS is
compared with DFO-pPhe-NCS, which is commercially
available from Macrocyclics under the name p-SCN-Bn-de-
feroxamine. Both compounds have the same p -
isothiocyanatophenylurea linker attached to DFO or DFO*,
respectively, and will be designated 89Zr-DFO(*)-mAb
throughout the manuscript. The human gastric cancer cell line
NCI-N87 was obtained from ATCC (United Kingdom) after
cytogenetic testing and used within 6 months after resuscita-
tion of the frozen cell line. The immunoreactivity was deter-
mined using SKOV-3 (HER2), A431 (EGFR), or SU-DHL-4
(CD20) cells essentially as described by Lindmo et al. [25].
89Zr (≥ 0.15 GBq/nmol in 1 mol/L oxalic acid) was obtained
from Perkin Elmer, Boston, USA.
General analyses and procedures
Cetuximab (5 mg/mL) was rebuffered to 0.9 % NaCl with the
aid of size exclusion chromatography using PD10 columns
(GE Healthcare Life Sciences) and re-concentrated to 5 or
5.77 mg/mL by a spin filter (Microcon-10 centrifugal filter,
Merck Millipore). Trastuzumab (21 mg/mL) and rituximab
(10 mg/mL) were used as such and diluted to 5 or 5.77 mg/
mL with 0.9 % NaCl.
Nanodrop analyses were performed on a NanoVue Plus
(GE Healthcare Life Sciences). Spin filter separation was per-
formed to determine the radiochemical purity. To this end
4 μL of sample was diluted with 96 μL eluent (5 % DMSO
and 95 % 20 mM histidine/240 mM sucrose buffer pH 5.5–
5.8) and applied on a microcon-30 centrifugal filter unit
(Ultracel YM-30, regenerated cellulose, 30 kDa cut-off,
Merck Millipore). The solution was spun down for 7 min at
14,000 rpm (Eppendorf 5430). The filter was washed twice
with 100 μL eluent and spun down at 14,000 rpm for 7 min
after each wash step. The filtrate contained free 89Zr/89Zr-
DFO(*), while the radiolabeled mAb was left on the filter.
Size exclusion (SE)-HPLC was performed to determine pro-
tein integrity and radiochemical purity. SE-chromatography
was performed on a Jasco HPLC system equipped with a
superdexTM 200 10/30 GL size exclusion column (GE
Healthcare Life Sciences) or Zenix SEC-300 (3 μm, 300 Å,
7.8x50 mm, Sepax) column including a guard column using a
mixture of 0.05M sodium phosphate, 0.15M sodium chloride
(pH 6.8), and 0.01 M NaN3 as the eluent at a flow rate of
0.5 mL/min or 1 mL/min, respectively. The radioactivity of
the eluate was monitored using an inline NaI(Tl) radiodetector
(Raytest Sockett). HPLC monitoring of the final products was
performed on a Jasco HPLC system using a superdex 200
column. Serum stability samples were analysed on a Zenix
SEC-300 using the same eluent as the superdex 200 column.
The iTLC analysis was performed to determine the
radiolabeling efficiency of DFO*-pPhe-NCS and DFO-
pPhe-NCS with 89Zr using iTLC-SG (Agilent Technologies,
Santa Clara, CA, USA) and 50 mM DTPA pH = 7 as mobile
phase (11.5 cm strip, 8 min run time). 89Zr-DFO*-pPhe-NCS
had a Rf = 0–0.25,
89Zr-DFO-pPhe-NCS a Rf = 0, and free
89Zr a Rf = 1.
Preparation of 89Zr-DFO*-mAb and 89Zr-DFO-mAb
The pH of the mAb solution (5 mg/mL) was adjusted to 8.9-
9.1 with 0.1 M Na2CO3. This solution was added to 3 eq. of
DFO*-pPhe-NCS or DFO-pPhe-NCS in DMSO (2 v/v%
compared to aqueous solution) and incubated for 30 min in
a Thermomixer (550 rpm) at 37 °C. After 30 min, non-
conjugated hydrolysed chelator was removed by size exclu-
sion chromatography using a PD-10 column and 0.9 % NaCl
or 20 mM histidine + 240 mM sucrose pH 5.5–5.8 as eluent
(same eluent used as after radiolabeling). The concentration of
the product was determined by spectrophotometry at 280 nm
using NanoDrop or by a calibration curve on a superdex 200
column. Subsequently, DFO*-mAb or DFO-mAb was
radiolabeled with 89Zr at room temperature for 60 min.
Typically, for a 1 mL reaction the following protocol was
used: to 100 μL 89Zr (∼50 MBq) in 1 M oxalic acid solution,
45 μL 2 M Na2CO3 was added and reacted for 3 min.
Subsequently, 150 μL 0.5 M HEPES buffer (pH 7.0),
355 μL (0.5 mg) DFO*-mAb, or DFO-mAb and 350 μL
0.5 M HEPES (pH 7.0) were added (the second portion of
HEPES may be added with the first portion, as long as the
reaction is properly mixed after the addition of mAb). Finally,
89Zr-DFO*-mAb or 89Zr-DFO-mAb was purified by size ex-
clusion chromatography (PD10 column). The concentration
of DFO(*)-mAbs was determined by SE-HPLC on a Zenix
SEC-300 column. For in vitro stability experiments with
trastuzumab, the product was formulated to 0.2 mg/mL and
10 MBq/mL (50 MBq/mg) (see in vitro stability section for
buffer composition).
Chelator-to-mAb ratio of 89Zr-DFO*-mAb
and 89Zr-DFO-mAb
The chelator-to-mAb ratio was determined by prelabeling the
chelator and the subsequent conjugation of 89Zr-chelator as
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well as by an isotopic dilution assay essentially as described
by Meares et al. [26].
Prelabeling the bifunctional chelator: to 20 μL 89Zr (2–
5 MBq) in 1 M oxalic acid solution, 100 μL 0.9 % NaCl
and 9 μL 2 M Na2CO3 were added and reacted for 3 min.
Subsequently, 100 μL 0.5 M HEPES buffer (pH 7.0) and
40 μL DFO*/DFO-pPhe-NCS (5 mM) in DMSO were added.
After 5 min, half of the volume (134.5 μL) was transferred to
an Eppendorf vial, and to this solution 865.5 μL trastuzumab,
rituximab or cetuximab (5.77 mg/mL) were added (final con-
centration: 5 mg/mL mAb). The pH was set to 8.9-9.1 with
2 M Na2CO3, and the reaction incubated for 30 min in a
Thermomixer (550 rpm) at 37 °C. Finally, 89Zr-DFO*-
mAb/89Zr-DFO-mAb was purified by size exclusion chroma-
tography (PD10 column) and the conjugation efficiency
determined.
Isotopic dilution assay: the DFO(*)-to-trastuzumab and
DFO(*)-to-rituximab molar ratios were determined following
a general method as described by Meares et al. [26]. In short,
conjugates were labelled according to the aforementioned pro-
cedure with a known excess of zirconium oxalate spiked with
89Zr.
In vitro stability (aqueous solutions and blood serum)
The in vitro stability was evaluated in two sets of experiments.
In a first set of experiments, the products were formulated at
0.2 mg/mL and 10 MBq/mL (50 MBq/mg) and stored at 4 °C
and room temperature in two different solutions: 0.9 % NaCl
or 20 mM histidine + 240 mM sucrose, pH 5.5-5.8. After 24,
48, 72, and 168 h samples were analysed for radiochemical
purity by a spin filter and immunoreactivity by a Lindmo
assay. In a second set of experiments, the formulated products
in 0.9 % NaCl was mixed with freshly prepared human blood
serum at a 1:1 ratio, and 0.02 % sodium azide was added. The
samples were incubated at 37 °C in a CO2-enriched atmo-
sphere (5 % CO2). At various time points, aliquots were taken
and analysed for radiochemical purity by SE-HPLC on a
Zenix SEC-300 column and for immunoreactivity by a
Lindmo assay. In the case of serum, SE-HPLC was used for
analysis of radiochemical purity, because spin filters gave less
reproducible results.
Evaluation of in vivo biodistribution
The biodistribution of both 89Zr-DFO*-trastuzumab and 89Zr-
DFO-trastuzumab was evaluated in N87 tumor bearing mice.
Female mice (HSD:Athymic Nude-Foxn1nu, 21–31 g;
Harlan) were 8 to 10 weeks old at the time of the experiments.
All animal experiments were done according to the NIH
Principles of Laboratory Animal Care and Dutch national
law (BWet op de dierproeven^, Stb 1985, 336). Mice bearing
N87 xenografts (two groups of n = 18) were anesthetised by
inhalation of 2 % isoflurane and injected intravenously (i.v.)
via the retroorbital plexus with either 100 μg 89Zr-DFO-
trastuzumab or 89Zr-DFO*-trastuzumab (2 MBq) in 20 mM
histidine + 240 mM sucrose, pH 5.5-5.8. Unlabeled
trastuzumab was added to the injection mixture to bring the
total mAb dose to 100 μg per mouse. At 1, 4, 24, 48, 72, and
144 h p.i., blood samples were drawn to determine the blood
kinetics. At 24, 72, and 144 h p.i., six mice of each group were
anesthetised, bled, killed, and dissected. After blood, tumor,
and normal tissues had been weighed, the amount of radioac-
tivity in each sample was measured in a gamma counter.
Radioactivity uptake was calculated as the percentage of the
injected dose per gram of tissue (%ID/g).
PET study
PET imaging was performed on a dedicated small animal
NanoPET/CT scanner (Mediso Ltd., Hungary, Szanda et al.).
N87 xenograft-bearing nude mice (n = 1 for each conjugate)
from the 144 h biodistribution timepoint were anesthetised by
inhalation of 2 % isoflurane and scanned at 72 h p.i. for 1 h. A
CT scan was acquired prior to the PET scan and used for
attenuation and scatter correction purposes. Reconstruction
was performed with a fully 3-dimensional (3-D) reconstruc-
tion (Tera-Tomo; Mediso Ltd.) with four iterations and six
subsets, resulting in an isotropic 0.4 mm voxel dimension.
The scanner was cross-calibrated with the dose calibrator
and well counter, enabling the derivation of accurate SUV
measures.
Statistical analyses
Statistical analysis was performed on pharmacokinetics, tissue
uptake, and tumor-to-blood ratios between different groups of
mice with the Welch’s T-test (SPSS) for paired data. Two-
sided significance levels were calculated and p < 0.01 was
considered as statistically significant.
Results
DFO*-pPhe-NCS was prepared from DFO* [24] in a single
step by reaction with p-phenylenediisothiocyanate (Fig. 1).
The product was purified by preparative HPLC and isolated
in a satisfying chemical yield with a purity of >95% according
to HPLC at 275 nm and NMR (Figure S1-4). For conjugation
to mAbs, the product was dissolved in DMSO.
89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab
were prepared similarly to postlabeling procedures de-
scribed by Vosjan et al. [6]. Protein aggregation during
modification was observed when using the Vosjan method,
which could be minimised by adapting the reagent addition
procedure. Instead of adding small portions of the chelator
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in DMSO to the mAb solution, the mAb was added at once
to the chelator in DMSO. This way, the protein integrity
was preserved, showing a single IgG peak at 280 nm at SE-
HPLC. All conjugates could be radiolabeled efficiently
(>80 % radiolabeling yield with 0.5 mg/mL mAb) and
had a radiochemical purity of >97.5 % and optimal immu-
noreactive fraction (>96 %). This is also true for cetuximab
and rituximab, which could be radiolabeled with the same
efficiency and radiochemical purity and an immunoreac-
tive fraction ≥90 % (see supporting information).
The DFO to mAbmolar ratios as determined by the isotope
dilution assay were 0.9 ± 0.1 (n = 6) and 1.3 ± 0.1 (n = 3) for
trastuzumab and rituximab, respectively, and the DFO* to
mAb ratios were 0.6 ± 0.1 (n = 4) and 0.8 ± 0.1 (n = 4) for
trastuzumab and rituximab, respectively.
Interestingly, when DFO*-pPhe-NCS and DFO-pPhe-NCS
were first radiolabeled with 89Zr and subsequently conjugated
to the mAb (prelabeling approach), only for DFO* radiolabeled
mAb was obtained. Although DFO*-pPhe-NCS and DFO-
pPhe-NCS did radiolabel efficiently (after 5 min at room tem-
perature both compounds were >95 % radiolabeled as deter-
mined by iTLC), 89Zr-DFO-pPhe-NCS did not conjugate to
mAbs at all. In contrast, in the case of DFO*, the applied 3:1
conjugation ratio of 89Zr-DFO*-pPhe-NCS to mAb resulted in
43 ± 2, 63 ± 1 and 43 ± 2 % radiolabeled product and, thus, a
1.3, 1.9, and 1.3 chelator-to-mAb ratio for trastuzumab (n = 4),
rituximab (n = 2), and cetuximab (n = 2), respectively.
89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab ob-
tained by standard post radiolabeling procedures were stored
at 4 °C and room temperature in 0.9 % NaCl and 20 mM
histidine/240 mM sucrose pH 5.5-5.8 up to 7 days to evaluate
the in vitro stability. In 0.9 % NaCl, 89Zr-DFO*-trastuzumab
outperformed 89Zr-DFO-trastuzumab in terms of stability (see
Table 1 and Table S1); while at 4 °C only 57.6 % intact 89Zr-
DFO-trastuzumab was left after 3 days, 89Zr-DFO*-
trastuzumab was still 94.5 % intact after the same period of
time. At room temperature, the percentage of intact tracer was
41.1% for 89Zr-DFO-trastuzumab and 90.7% for 89Zr-DFO*-
trastuzumab. In 20 mM histidine/240 mM sucrose, the prod-
ucts exhibited no difference in stability. Both compounds were
>92 % intact after 3 days of storage at 4 °C or room temper-
ature. The immunoreactivity of the products, not corrected for
free radioactivity, decreased accordingly and was following
the same trend as the radiochemical purity. Also in vitro sta-
bility studies in human serum/0.9 % NaCl (1:1) showed that
89Zr-DFO*-trastuzumab is more stable than 89Zr-DFO-
trastuzumab. After 72 h at 37 °C, 97.5 % and 77.7 % intact
tracer was left, respectively. Immunoreactivity determined by
the Lindmo binding assay showed the same trend and an im-
munoreactive fraction of 91 % and 74 % was observed after
72 h at 37 °C for 89Zr-DFO*-trastuzumab and 89Zr-DFO-
trastuzumab, respectively.
89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab were
injected into N87 tumor-bearing nude mice. At 1, 4, 24, 48,
72, and 144 h p.i., blood samples were drawn and the % ID/g
determined. At 24, 72, and 144 h p.i., the %ID/g uptake in
tumor and normal tissue was determined. Blood kinetics were
similar (see Fig. 2). At 144 h p.i., blood kinetics and tumor
uptake were not significantly different, while bone-containing
organs, skin, liver, spleen, and ileum showed a significantly
lower uptake level in case of DFO* (see Fig. 3). Uptake of
89Zr-DFO*-trastuzumab in bone-containing organs decreased
over time, while the uptake of 89Zr-DFO-trastuzumab increased
(see Figure S5). As a result, ratios of 89Zr-DFO-trastuzumab
Fig. 1 Synthesis of 89Zr-DFO*-mAbs: a Et3N, iPropOH/H2O/CHCl3, RT, 18 h; b 30 min 37 °C, RT; c 60 min RT
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over 89Zr-DFO*-trastuzumab in bone-containing organs in-
creased over time (see Figure S6). At 24 h p.i., the ratio was
1.3 in sternum and 1.5 in femur; at 72 h p.i. 1.7 in sternum, 2.1
in femur, and 2.8 in knee; and at 144 h p.i., 3.6 in sternum, 5.0
in femur, and 5.9 in knee (see Figure S6).
PET imaging studies were performed to evaluate 89Zr-
DFO(*)-trastuzumab uptake also in tissues not evaluated in
the ex vivo biodistribution experiment. Movies of PET images
that were obtained 72 h p.i. are provided in the supporting
information. While tumor uptake was clearly visible for both
89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, 89Zr-
DFO*-trastuzumab showed less bone uptake than 89Zr-
DFO-trastuzumab (see Fig. 4).
Discussion
In the present study, we describe a new bifunctional
octadentate chelator for 89Zr, which holds great promise to
improve clinical 89Zr-immuno-PET performance.
Previously, we reported the synthesis of DFO* and the
superior in vitro stability of its complex with 89Zr in compar-
ison to 89Zr-DFO, also when challenged with an excess of
DFO [24]. Here, we describe the synthesis of a bifunctional
version of this chelator, DFO*-pPhe-NCS. This bifunctional
chelator is prepared starting from the commercially available
DFO, which makes DFO*-based chelating agents attractive
candidates for commercialization and wide spread use in clin-
ical nuclear medicine. The GMP compliant synthesis of 89Zr-
DFO-mAb conjugates has been described before [6] and 89Zr-
DFO*-mAbs are prepared in a similar manner. The only dif-
ference is a small adjustment of the conjugation protocol,
which resulted in improved integrity for the 89Zr-DFO(*)-
mAb conjugates. The addition of small portions of the chela-
tor in DMSO to mAbs can result in protein aggregation. To
prevent this, the addition order was reversed, and the protein
added to the chelator instead. In this way protein aggregation
could be minimised. The conjugation of DFO*-pPhe-NCS
Fig. 2 Blood kinetics of 89Zr-DFO*-trastuzumab (black line) and 89Zr-
DFO-trastuzumab (grey line) in N87 tumor-bearing nude mice up to
144 h after administration
Table 1 In vitro stability of 89Zr-DFO*-trastuzumab (A) and 89Zr-DFO-trastuzumab (B) at 4 °C in 20 mM histidine + 240 mM sucrose or 0.9 % NaCl
or at 37 °C in serum
A 20 mM Histidine/240 mM sucrose 0.9 % NaCl Serum













0 h 99.0 98 98.0 97 100.0 97
24 h 98.4 97 97.8 95 100.0 nd
48 h 97.7 96 95.1 93 99.2 nd
72 h 97.0 94 94.5 91 97.5 91
168 h 92.5 90 89.1 82 96.3 88
B 20 mM Histidine/240 mM sucrose 0.9 % NaCl Serum













0 h 97.8 96 98.6 97 100.0 97
24 h 97.2 95 88.5 81 88.6 85
48 h 96.0 93 65.8 nd 82.3 79
72 h 94.9 93 57.6 nd 77.7 74
168 h 90.5 87 50.4 nd 72.0 64
nd not determined
Radiochemical purity of buffer samples determined by a spin filter
Radiochemical purity of serum samples determined by SEC-HPLC
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was slightly less effective, but the subsequent radiolabeling
efficiency was similar for both chelators. For DFO-pPhe-
NCS, the same chelator-to-mAb ratios and radiolabeling effi-
ciencies were achieved as reported by Vosjan et al. [6]. Using
a prelabeling approach, we found that 89Zr-DFO-pPhe-NCS
could not be conjugated to mAbs anymore, while 89Zr-DFO*-
pPhe-NCSwas still capable of conjugation. This indicates that
the isothiocyanate linker may be coordinated to 89Zr in case of
DFO and, consequently, is not available anymore for
bioconjugation. The same accounts for the N-suc-DFO chela-
tor. When N-suc-DFO was first radiolabeled with Zr-89, the
COOH group could not be transformed into the TFP-ester
anymore [10]. In the case of DFO*; however, 89Zr is
coordinatively saturated by the chelator, and; therefore, the
Fig. 3 Biodistribution of 89Zr-
DFO*-trastuzumab (black bars)
and 89Zr-DFO-trastuzumab (grey
bars) in N87 tumor-bearing nude
mice at 24 h a, 72 h b, and 144 h c
after administration. Total
administered dose 100 μg. Mean
(%ID/g) ± SD at each time point
after injection (n = six animals per
time point per conjugate).
(Significant differences (P < 0.05)
in biodistribution between both
radioimmunoconjugates are
marked with an asterisk)
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isothiocyanate linker is left available for bioconjugation. This
interesting difference now allows prelabeling strategies with
89Zr using DFO*, which was not possible before with DFO
derivatives. Prelabeling with 89Zr-DFO*-pPhe-NCS could be
an advantageous approach in the case of labeling of small
amounts of mAb, cells [27], or mAbs with supertoxic
payloads, since the number of handlings of the mAb is re-
duced from two to one.
The coordinative saturation of 89Zr in DFO* manifested
itself also in vitro and in vivo. While the stability of 89Zr-
DFO-trastuzumab with thiourea linker is strongly dependent
on the storage conditions with respect to buffer composition,
Fig. 4 Coronal PET images of
N87 tumor-bearing nude mice
acquired 72 h after injection of
100 μg, 2 MBq of either 89Zr-
DFO*-trastuzumab a or 89Zr-
DFO-trastuzumab b.Tumor are
indicated with white arrows, bone
uptake is indicated with yellow
arrows
Table 2 Biodistribution of 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab in N87 tumor-bearing nude mice at 24, 72, and 144 h after
administration
24 hr 72 hr 144 hr
DFO* DFO DFO* DFO DFO* DFO
Blood 13.45 ± 1.20 16.16 ± 1.47 10.06 ± 1.22 9.49 ± 2.13 3.73 ± 1.84 3.50 ± 2.41
Tumor 27.81 ± 7.44 26.23 ± 4.31 47.70 ± 5.52 35.54 ± 4.08 32.59 ± 11.95 29.06 ± 8.66
Skin 5.37 ± 0.75 6.31 ± 0.89 3.80 ± 0.34 5.51 ± 0.73 1.88 ± 0.43 2.71 ± 0.64
Tongue 4.69 ± 0.36 5.74 ± 0.67 3.44 ± 0.33 3.52 ± 0.47 1.31 ± 0.60 1.60 ± 0.76
Sternum 2.10 ± 0.24 2.79 ± 0.39 1.72 ± 0.16 2.97 ± 0.15 0.92 ± 0.16 3.33 ± 0.32
Heart 3.41 ± 0.34 4.45 ± 0.58 2.82 ± 0.49 2.90 ± 0.56 1.07 ± 0.35 1.25 ± 0.41
Lung 5.41 ± 0.48 6.73 ± 1.28 4.43 ± 0.62 4.52 ± 0.83 2.18 ± 0.88 2.32 ± 0.87
Liver 4.47 ± 1.07 5.11 ± 1.26 4.05 ± 0.63 7.27 ± 0.35 3.17 ± 0.82 6.43 ± 1.64
Spleen 3.36 ± 0.99 3.95 ± 0.68 2.68 ± 0.23 3.22 ± 0.30 1.65 ± 0.34 3.26 ± 1.05
Kidney 3.43 ± 0.48 4.41 ± 0.70 3.51 ± 0.78 5.08 ± 0.81 2.75 ± 0.42 3.35 ± 0.62
Bladder 3.75 ± 0.28 4.56 ± 0.19 3.65 ± 0.46 4.04 ± 0.41 1.65 ± 0.50 2.01 ± 0.40
Muscle 1.90 ± 0.13 2.23 ± 0.17 1.34 ± 0.24 1.44 ± 0.05 0.46 ± 0.17 0.65 ± 0.27
Femur 1.43 ± 0.08 2.15 ± 0.34 1.21 ± 0.06 2.54 ± 0.25 0.78 ± 0,.11 3.85 ± 0.80
Colon 1.42 ± 0.08 1.79 ± 0.25 1.18 ± 0.19 1.41 ± 0.15 0.74 ± 0.29 1.06 ± 0.28
Ileum 1.48 ± 0.21 2.03 ± 0.28 1.09 ± 0.09 1.57 ± 0.20 0.60 ± 0.10 1.34 ± 0.70
Stomach 1.61 ± 0.25 1.97 ± 0.20 1.33 ± 0.18 1.57 ± 0.27 0.67 ± 0.14 0.94 ± 0.12
Knee n.d. n.d. 2.07 ± 0.15 5.70 ± 1.51 1.38 ± 0.23 8.20 ± 2.94
Total administered dose 100 μg. Mean (%ID/g) ± SD at each time point after injection (n = six animals per time point and conjugate)
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this is less critical for the thiourea-linked 89Zr-DFO*-
trastuzumab. In previous experiments, we found that 89Zr-
DFO-mAbs having a thiourea linker between DFO and the
mAb should preferably not be stored in sodium chloride-
containing buffers. We postulated that the presence of Cl− ions
affected the stability of 89Zr-labeled mAb due to radiation-
induced formation of hypochlorite ions reacting with the
enolised thiourea unit. Mixing of 89Zr-DFO-trastuzumab
stored in 0.9 % NaCl with serum resulted in an increased
stability, most probably because sulphur atoms of the serum
proteins act as scavenging matter for the hypochlorite. The
results in Table 1 show that 89Zr-DFO*-mAb with the same
thiourea linker is far less sensitive to the presence of Cl−. This
indicates that in case of DFO-pPhe-NCS, the enolised sulphur
atom of the thiourea unit is coordinated to 89Zr and subse-
quently oxidised by hypochlorite. These results suggest that
the unsaturated coordination of 89Zr is causing the observed
impaired stability of the 89Zr-DFO complex, which is not seen
with the new chelator DFO*.
Although blood kinetics and tumor uptake in mice were
similar for 89Zr-DFO*-trastuzumab and 89Zr-DFO-
trastuzumab, 89Zr-DFO*-trastuzumab showed a significantly
lower uptake in bone containing organs, skin, liver, spleen,
and ileum than 89Zr-DFO-trastuzumab (Table 2). Actually,
over time the bone uptake of 89Zr-DFO-trastuzumab in-
creased, while the uptake of 89Zr-DFO*-trastuzumab de-
creased (see Figure S5). Thus, DFO* indeed provides a prod-
uct that is more stable in vivo, since 89Zr becomes less easily
released from the chelator. Recently, much effort has been put
in developing improved bifunctional chelators for 89Zr [16,
19, 20, 23]. Focusing on the bifunctional chelators that coor-
dinate 89Zr efficiently, four molecules have been reported.
Derivatised fusarinine C (FSC) [20] a cyclic hexadentate che-
lator, has been tested in combination with a RGD-peptide.
Only short-term in vivo experiments are reported, and the
performance with longer circulating biologicals is not yet
known. Next, there are two 89Zr-HOPO-trastuzumab com-
plexes reported [16, 23]. Deri et al. reported on 89Zr-
3,4,3-(LI-1,2-HOPO)-mAb [16]. Although less bone uptake
was observed for 89Zr-3,4,3-(LI-1,2-HOPO)-trastuzumab
compared to 89Zr-DFO-trastuzumab, the tumor uptake also
decreased to half of the uptake observed with 89Zr-DFO-
trastuzumab. Tinianow et al. reported on 89Zr-2,3-HOPO-
trastuzumab [23]. In vitro serum stability, radiochemical puri-
ty of the 89Zr-labeled mAb complex and in vivo bone uptake
were less favorable for 89Zr-2,3-HOPO-mAb compared to
89Zr-DFO-mAb. Finally, Boros et al. reported on a
macrocycle-based hydroxamate chelator L5 [19]. Although
in vitro stability of their 89Zr-chelator was similar to 89Zr-
DFO, its bifunctional variant coupled to trastuzumab showed
higher bone uptake and faster blood clearance than 89Zr-DFO-
trastuzumab. Though a direct comparison of the described
hexadentate/octadentate bifunctional chelators for 89Zr is
difficult, indications are that DFO* is the best qualified with
respect to tumor targeting and in vitro and in vivo stability.
Conclusion
89Zr-DFO*-mAbs can be prepared analogously to 89Zr-DFO-
mAbs resulting in radioimmunoconjugates with high radio-
chemical purity and optimal immunoreactivity. The in vitro
serum stability of 89Zr-DFO*-trastuzumab outperformed 89Zr-
DFO-trastuzumab. In vivo 89Zr-DFO*-trastuzumab showed
comparable tumor targeting and blood kinetics as 89Zr-DFO-
trastuzumab, but less uptake in bone-containing organs, skin,
liver, spleen, and ileum. This makes DFO* a candidate suc-
cessor of DFO for clinical 89Zr-immuno-PET.
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